Safety and Functional Outcomes Following Total Hip Arthroplasty Using the Latitud™ Total Hip Replacement System in Patients With Hip Fracture

Background Hip fractures, particularly among the aging population, present a significant burden due to their association with morbidity, mortality, and long-term disability. Total hip arthroplasty (THA) is increasingly being adopted for fracture management in active patients, but implant performance data in real-world Indian settings remain sparse. This study assesses the early clinical efficacy, functional outcomes, and implant survivorship of the Latitud™ total hip replacement system (HRS) (Meril Healthcare Pvt. Ltd., Vapi, India), a novel prosthesis designed and manufactured in India, in patients undergoing THA for hip fractures. Methods This post hoc analysis derives from a prospective, multi-center, post-marketing surveillance study conducted across 11 tertiary care centers in India. A total of 44 adult patients presenting with various fracture patterns, including femoral neck, femoral head, intertrochanteric, sub-capital, and head-neck fractures, were evaluated following THA using the Latitud™ HRS. The primary objectives of the study were implant survivorship and adverse events over a two-year follow-up period, whereas the secondary objective of the study was to assess functional outcomes using the Harris hip score (HHS) and Oxford hip score (OHS) at six weeks, six months, one year, and two years postoperatively. Paired t-tests or Wilcoxon signed-rank tests were used for statistical comparisons, with p < 0.05 considered significant. Results A total of 44 patients were identified with the following fracture types: femoral neck (n = 18), femoral head (n = 8), head-neck (n = 2), and hip fractures (n = 12), with one case each of intertrochanteric, subcapital, intracapsular neck of femur (ICNF), and neck of femur fractures due to fall at home. Functional outcomes significantly improved, with the mean HHS increasing from 9.19 ± 9.52 preoperatively to 89.61 ± 3.57 (p < 0.0001), and the OHS from 4.89 ± 4.41 to 44.89 ± 3.77 (p < 0.0001). No serious adverse events were observed apart from the isolated revision case. At two years, implant survivorship was 97.7%, with a single revision due to polyethylene liner fracture. No other major complications, including infections, dislocations, or periprosthetic fractures, were reported. Conclusion The Latitud™ HRS demonstrated excellent short-term survivorship and marked functional improvement in patients with hip fractures, with minimal complications. These findings support its safety and effectiveness in the Indian clinical context and suggest its potential as a reliable implant for fracture-related THA. Further large-scale, long-term comparative studies are warranted to confirm these outcomes.